The specificities of tau and a-syn analysis in neuronal disease patients, which were used as test set_B, were higher (86.67%–93.33%) than these values in the non-CJD group (74.61%–80.86%). This evidence concerns the gene MAPT and Creutzfeldt Jacob disease.